XNCR
Xencor, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Buy
+42/100
Last price
24.36
▼ 1.27 (4.96%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
25.65
Prev close
25.63
Day high
26.03
Day low
23.89
Volume
1.25M
Market cap
$1.81B
P/E (TTM)
—
52W range
10.38 – 30.61
Day trading desk
Gap from prior close
+0.08%
Prior close 25.63
VWAP
24.43
-0.30% from price
Relative volume
1.77×
Unusually busy
Session range
12.10%
23.89 – 26.78
Position in range
16%
Near session low
ATR (14D)
1.26
5.18% of price
Prior day high
26.01
PDH
Prior day low
24.83
PDL
Bid / ask spread
—
Quote not published
Session volume
2.28M
Avg 1.29M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.56%
-4.5%
1M
-8.46%
-9.6%
3M
+48.00%
+43.5%
6M
+97.89%
+79.7%
YTD
+59.11%
+44.9%
1Y
+106.97%
+90.5%
3Y
+20.89%
-61.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on XNCR open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+48.53K
Net buying
Buy transactions
8
82.42K shares
Sell transactions
6
33.88K shares
Net transactions
+14
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
907.11K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 18, 26 | FEIGAL ELLEN G. Director |
SELL | 6.84K | $89.37K | Direct |
| Jun 16, 26 | MONTGOMERY ALAN BRUCE Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | SIMPSON TODD E Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | RANIERI RICHARD J Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | GORMAN KEVIN CHARLES Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | GUSTAFSON KURT A Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | KLENCKE BARBARA M.D. Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | FEIGAL ELLEN G. Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | DESHAIES RAYMOND JOSEPH Director |
STOCK | 10.30K | $0 | Direct |
| Jun 15, 26 | MONTGOMERY ALAN BRUCE Director |
SELL | 5.06K | $62.34K | Direct |
| Jun 15, 26 | RANIERI RICHARD J Director |
SELL | 5.47K | $67.39K | Direct |
| Jun 15, 26 | GORMAN KEVIN CHARLES Director |
SELL | 7.53K | $92.66K | Direct |
| Jun 15, 26 | GUSTAFSON KURT A Director |
SELL | 5.47K | $67.39K | Direct |
| Apr 10, 26 | CORNELISSEN BART JAN Chief Financial Officer |
SELL | 3.50K | $42.99K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CORNELISSEN BART JAN |
Chief Financial Officer | 75.90K | Sale |
DAHIYAT BASSIL ISHMAEL |
Chief Executive Officer | 546.32K | Sale |
DESJARLAIS JOHN R |
Officer | 263.83K | Sale |
ECKERT CELIA E |
General Counsel | 76.92K | Sale |
GUSTAFSON KURT A |
Director | 25.01K | Stock Award(Grant) |
KLENCKE BARBARA M.D. |
Director | 29.97K | Stock Award(Grant) |
MONTGOMERY ALAN BRUCE |
Director | 25.85K | Stock Award(Grant) |
RANIERI RICHARD J |
Director | 24.01K | Stock Award(Grant) |
SIMPSON TODD E |
Director | 23.99K | Stock Award(Grant) |
VALENTE NANCY |
Officer | 49.17K | Sale |
Fundamentals
Market cap$1.81B
Enterprise value$1.52B
Revenue (TTM)$104.97M
Gross profit$-150.79M
EBITDA$-205.90M
Net income$-163.32M
EPS (TTM)$-2.05
Free cash flow$-94.54M
Total cash$456.45M
Total debt$170.11M
Book value / share$6.77
Shares outstanding74.35M
Float54.25M
Short % of float30.05%
Dividend yield0.00%
Beta (5Y)0.90
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.85
PEG ratio—
Price / sales—
Price / book3.60
EV / revenue14.53
EV / EBITDA-7.41
Gross margin-143.65%
Operating margin-72.37%
Profit margin-155.59%
Return on equity-29.07%
Return on assets-16.84%
Debt / equity33.80
Current ratio6.39
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $125.58M | $110.49M | $174.62M | $164.58M | +13.7% |
| Operating revenue | $125.58M | $110.49M | $174.62M | $164.58M | +13.7% |
| Research & development | $239.43M | $227.69M | $253.60M | $199.56M | +5.2% |
| Selling, general & admin | $63.64M | $61.22M | $53.38M | $47.49M | +4.0% |
| Total operating expense | $303.08M | $288.90M | $306.98M | $247.05M | +4.9% |
| Operating income | -$177.50M | -$178.41M | -$132.36M | -$82.47M | +0.5% |
| Net interest income | -$4.40M | -$4.71M | $13.15M | $4.82M | +6.6% |
| Pre-tax income | -$89.63M | -$234.92M | -$119.63M | -$54.51M | +61.8% |
| Tax provision | $2.50M | $1.62M | $13.66M | $673.00K | +54.9% |
| Net income | -$91.92M | -$232.62M | -$133.13M | -$55.18M | +60.5% |
| Net income to common | -$91.92M | -$232.62M | -$133.13M | -$55.18M | +60.5% |
| Basic EPS | -1.24 | -3.58 | -2.08 | -0.93 | +65.4% |
| Diluted EPS | -1.24 | -3.58 | -2.08 | -0.93 | +65.4% |
| EBIT | -$57.71M | -$198.28M | -$113.46M | -$54.49M | +70.9% |
| EBITDA | -$47.19M | -$186.17M | -$101.96M | -$45.70M | +74.7% |
| Basic shares | 74.24M | 65.04M | 60.50M | 59.65M | +14.1% |
| Diluted shares | 74.24M | 65.04M | 60.50M | 59.65M | +14.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $54.07M | $40.88M | $53.79M | $53.94M | +32.3% |
| Cash & short-term investments | $547.73M | $497.77M | $593.73M | $623.06M | +10.0% |
| Accounts receivable | $29.30M | $60.85M | $23.74M | $29.00M | -51.8% |
| Total current assets | $599.82M | $577.60M | $635.60M | $675.34M | +3.8% |
| Property, plant & equipment | $90.90M | $98.14M | $100.12M | $93.60M | -7.4% |
| Goodwill & intangibles | $8.38M | $18.48M | $18.66M | $18.50M | -54.6% |
| Total assets | $875.50M | $951.95M | $965.13M | $846.27M | -8.0% |
| Total current liabilities | $95.91M | $87.43M | $73.92M | $63.84M | +9.7% |
| Current debt | $43.27M | $48.45M | $27.71M | — | -10.7% |
| Long-term debt | $76.48M | $115.16M | $161.77M | — | -33.6% |
| Total debt | $187.75M | $231.95M | $251.94M | $59.63M | -19.1% |
| Total liabilities | $239.91M | $277.92M | $303.05M | $118.77M | -13.7% |
| Retained earnings | -$795.96M | -$704.04M | -$471.42M | -$338.29M | -13.1% |
| Shareholder equity | $635.59M | $677.61M | $661.75M | $727.50M | -6.2% |
| Working capital | $503.91M | $490.17M | $561.69M | $611.50M | +2.8% |
| Net tangible assets | $627.20M | $659.13M | $643.09M | $709.00M | -4.8% |
| Shares issued | 71.87M | 70.26M | 61.00M | 60.00M | +2.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$92.14M | -$236.54M | -$133.30M | -$55.18M | +61.0% |
| Depreciation & amortisation | $10.51M | $12.11M | $11.50M | $8.80M | -13.2% |
| Stock-based compensation | $43.23M | $53.28M | $53.76M | $48.91M | -18.9% |
| Change in working capital | $47.45M | -$40.40M | $19.13M | $48.87M | +217.5% |
| Operating cash flow | -$135.12M | -$202.19M | -$77.93M | $24.48M | +33.2% |
| Capital expenditure | -$3.15M | -$9.51M | -$21.25M | -$43.40M | +66.9% |
| Investing cash flow | $139.99M | -$7.87M | -$111.06M | -$119.72M | +1,878.3% |
| Financing cash flow | $8.23M | $197.15M | $189.22M | $5.70M | -95.8% |
| Free cash flow | -$138.27M | -$211.70M | -$99.18M | -$18.92M | +34.7% |
| End cash position | $54.36M | $41.26M | $54.17M | $53.94M | +31.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $51.22M | $4.52M | $28.24M | $21.00M | $43.61M | +1,034.2% |
| Operating revenue | $51.22M | $4.52M | $28.24M | $21.00M | $43.61M | +1,034.2% |
| Research & development | $71.91M | $64.67M | $64.82M | $54.37M | $61.66M | +11.2% |
| Selling, general & admin | $16.38M | $17.71M | $17.04M | $14.15M | $15.12M | -7.5% |
| Total operating expense | $88.29M | $82.38M | $81.86M | $68.52M | $76.78M | +7.2% |
| Operating income | -$37.07M | -$77.86M | -$53.63M | -$47.52M | -$33.17M | +52.4% |
| Net interest income | -$2.55M | $759.00K | -$1.15M | -$1.13M | -$995.00K | -436.2% |
| Pre-tax income | -$21.92M | -$128.64M | -$4.27M | -$6.03M | -$31.07M | +83.0% |
| Tax provision | -$190.00K | $280.00K | $2.39M | $0 | -$250.00K | -167.9% |
| Net income | -$21.73M | -$128.92M | -$6.65M | -$6.03M | -$30.82M | +83.1% |
| Net income to common | -$21.73M | -$128.92M | -$6.65M | -$6.03M | -$30.82M | +83.1% |
| Basic EPS | -0.29 | -1.71 | -0.09 | -0.08 | -0.41 | +83.0% |
| Diluted EPS | -0.29 | -1.71 | -0.09 | -0.08 | -0.41 | +83.0% |
| EBIT | -$14.57M | -$123.94M | $3.09M | $1.64M | -$22.83M | +88.2% |
| EBITDA | -$12.13M | -$121.37M | $5.67M | $4.23M | -$20.18M | +90.0% |
| Basic shares | 75.86M | 75.25M | 74.59M | 74.41M | 74.28M | +0.8% |
| Diluted shares | 75.86M | 75.25M | 74.59M | 74.41M | 74.28M | +0.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $44.66M | $14.17M | $54.07M | $28.29M | $44.44M | +215.2% |
| Cash & short-term investments | $456.45M | $444.95M | $547.73M | $471.04M | $443.86M | +2.6% |
| Accounts receivable | $42.23M | $12.00M | $29.30M | $21.80M | $47.55M | +251.9% |
| Total current assets | $523.21M | $482.86M | $599.82M | $518.44M | $513.15M | +8.4% |
| Property, plant & equipment | $86.00M | $88.31M | $90.90M | $92.96M | $93.84M | -2.6% |
| Goodwill & intangibles | $6.52M | $7.60M | $8.38M | $9.47M | $11.25M | -14.2% |
| Total assets | $724.96M | $736.85M | $875.50M | $868.81M | $879.42M | -1.6% |
| Total current liabilities | $81.86M | $73.46M | $95.91M | $86.48M | $96.08M | +11.4% |
| Current debt | $27.36M | $26.41M | $43.27M | — | $50.29M | +3.6% |
| Long-term debt | $77.54M | $82.12M | $76.48M | — | $94.74M | -5.6% |
| Total debt | $170.11M | $175.16M | $187.75M | $69.27M | $212.95M | -2.9% |
| Total liabilities | $221.73M | $221.21M | $239.91M | $243.50M | $259.07M | +0.2% |
| Retained earnings | -$946.60M | -$924.88M | -$795.96M | -$789.31M | -$783.28M | -2.3% |
| Shareholder equity | $503.23M | $515.63M | $635.59M | $625.32M | $620.35M | -2.4% |
| Working capital | $441.35M | $409.40M | $503.91M | $431.96M | $417.07M | +7.8% |
| Net tangible assets | $496.70M | $508.03M | $627.20M | $615.85M | $609.10M | -2.2% |
| Shares issued | 74.33M | 74.06M | 71.87M | 71.34M | 71.30M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$21.73M | -$128.92M | -$6.65M | -$6.03M | -$30.82M | +83.1% |
| Depreciation & amortisation | $2.44M | $2.57M | $2.58M | $2.59M | $2.65M | -4.9% |
| Stock-based compensation | $9.19M | $9.56M | $10.19M | $10.09M | $10.74M | -3.9% |
| Change in working capital | -$22.85M | -$2.92M | $8.13M | $20.15M | -$6.11M | -681.3% |
| Operating cash flow | -$55.66M | -$67.63M | -$51.71M | -$30.82M | -$36.37M | +17.7% |
| Capital expenditure | -$538.00K | -$610.00K | -$1.14M | -$183.00K | -$383.00K | +11.8% |
| Investing cash flow | $85.12M | $26.68M | $71.17M | $14.67M | $40.48M | +219.1% |
| Financing cash flow | $1.03M | $950.00K | $6.32M | $0 | $662.00K | +8.5% |
| Free cash flow | -$56.20M | -$68.24M | -$52.85M | -$31.00M | -$36.75M | +17.6% |
| End cash position | $44.85M | $14.36M | $54.36M | $28.58M | $44.73M | +212.3% |
Options analytics
Put / call volume
0.05
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
17.50
-28.2% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
-6.2%
Calls bid over puts
Call volume
81
Contracts, this expiry
Put volume
4
Contracts, this expiry
Heaviest call OI
25.00
0 contracts
Heaviest put OI
17.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.84 | -0.29 | +65.6% |
| Mar 2026 | -0.75 | -1.71 | -129.0% |
| Dec 2025 | -0.58 | -0.09 | +84.6% |
| Sep 2025 | -0.70 | -0.08 | +88.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.40 | 12 | $59.07M | +181.3% |
| Next quarter | -0.82 | 12 | $28.39M | +0.5% |
| Current year | -3.15 | 12 | $143.22M | +14.1% |
| Next year | -3.56 | 12 | $121.64M | -15.1% |
Analyst targets & ownership
Mean target$31.42
High target$46.00
Low target$20.00
Implied upside28.97%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy3 / 9
Hold2
Sell / Strong sell0 / 0
Held by insiders1.22%
Held by institutions114.50%
Institutions holding302
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
24.71
-1.41% from price
SMA 20
24.61
-1.01% from price
SMA 50
24.39
-0.14% from price
SMA 100
19.21
+26.79% from price
SMA 200
15.97
+52.53% from price
EMA 12
24.84
-1.94% from price
EMA 26
24.74
-1.55% from price
EMA 50
23.52
+3.55% from price
RSI (14)
47.7
Neutral
MACD (12,26,9)
0.10
Hist -0.06
ATR (14)
1.26
5.18% of price
Realised vol 30D
51.9%
Annualised
Bollinger upper
25.71
20, 2σ
Bollinger lower
23.51
20, 2σ
50 / 200 cross
Golden
24.39 vs 15.97
Trend bias
Above 200
+52.53%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.16
More volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
51.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-42.6%
Peak to trough
Max drawdown 5Y
-83.9%
Peak to trough
ATR 14
1.26
5.18% of price
Beta (reported)
0.90
5Y monthly, from filing
Short interest
Shares short
15.75M
Prior 14.19M
Change vs prior
+11.0%
Shorts adding
% of float
30.05%
Heavily shorted
% of shares out
21.18%
Against total outstanding
Days to cover
11.2
Crowded exit
Float
54.25M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 28, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Sep 21, 26 | B of A Securities | MAINTAINED | Neutral | Neutral |
| Sep 11, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Sep 3, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Sep 1, 26 | Raymond James | MAINTAINED | Strong Buy | Strong Buy |
| Aug 6, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 6, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 6, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jul 30, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jul 7, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| May 11, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Mar 24, 26 | JP Morgan | DOWNGRADE | Overweight | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-06-18
Periodic Financial Reports
10-Q · 2026-05-06
Corporate Changes & Voting Matters
8-K · 2026-05-05
Corporate Changes & Voting Matters
8-K · 2026-04-27
Corporate Changes & Voting Matters
8-K · 2026-03-09
Corporate Changes & Voting Matters
8-K · 2026-03-04
Headlines
Raymond James Updates Healthcare Top Picks for October
Investing.com · 5d ago
Xencor's XmAb819 Data Could Support Registrational Path, Wedbush Says
MT Newswires · 11d ago
BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating
MT Newswires · 16d ago
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
GlobeNewswire · 30d ago
Xencor to Present at the 2026 Cantor Global Healthcare Conference
Business Wire · 34d ago
Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating
MT Newswires · 36d ago
How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit
Simply Wall St. · 60d ago
Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating
MT Newswires · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.